ClinicalTrials.gg
CompletedNCT04233814Updated Mar 7, 2022

Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects

A Phase 1 interventional study of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Lung Therapeutics, Inc. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-07.

Sponsored by Lung Therapeutics, Inc · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Dec 2021, 4 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom — 14 open to participants now, 22 under way, 4 of them phase 3. Idiopathic Pulmonary Fibrosis · United Kingdom.

Enrollment
49th of 83
71 · median 109
Started
2020
with 8 others
Phase 1
15 of 103
none open now
Registered
55th of 103
by date

Among the 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom, this one is the 49th largest by enrollment of the 83 interventional ones that give a count, is one of 9 that started in 2020, is one of 15 in phase 1, and was the 55th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

14 of the 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom, or all of them as a file.
02

Study summary

The current study will investigate the initial safety, tolerability, and PK profile of inhaled LTI-03 in healthy volunteers. In order to minimize exposure, the study will first test single ascending doses (SAD) of LTI-03 followed by multiple ascending dose (MAD) cohorts.

Findings from this study will direct the clinical development of LTI-03 for the treatment of IPF

The study subject population will include normal healthy male and female volunteers between 18 and 55 years of age (inclusive).

Consistent with other trials involving inhaled medication, subjects must have normal pulmonary function at Screening and will be excluded if they have a history of active or recurring allergies, asthma, chronic obstructive pulmonary disease (COPD), chronic sinus drainage, chronic or acute cough or other respiratory condition deemed exclusionary by the Investigator. History of liver dysfunction or elevated bilirubin, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values at Screening will also be grounds for exclusion.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Non-smoker (no use of tobacco products within 6 months prior to dosing) with a negative urine cotinine test at Screening or Day -1
  2. Age of 18-55 years (inclusive)
  3. (BMI) of 18 - 30.5 kg/m2 (inclusive)
  4. Body weight > 50 kg
  5. Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  1. History of asthma
  2. Presence of active or recurring allergies, asthma, (COPD), chronic sinus drainage, chronic or acute cough or other respiratory condition deemed exclusionary by the Investigator or designee
  3. Pulmonary infiltrate or pneumonia within 6 months prior to dosing or acute infection within 14 days prior to dosing
  4. History of significant allergy or anaphylaxis
  5. Any hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic or allergic disease (excluding hay fever), as determined by the Investigator or designee
  6. Any current clinically relevant abnormalities identified by a detailed medical history, complete physical examination including blood pressure and heart rate measurement, and clinical laboratory tests (hematology, coagulation, urinalysis, clinical chemistries) at Screening or Day -1, as determined by the Investigator or designee
  7. Any clinically significant illness and/or surgery within 28 days prior to dosing
  8. Febrile illness within 7 days prior to dosing
  9. Weight loss > 5 kg within 28 days prior to dosing
  10. Clinically significant 12-lead (ECG) abnormalities or vital sign abnormalities (systolic blood pressure \< 90 mmHg or > 140 mmHg, diastolic blood pressure \< 50 mmHg or > 90 mmHg, or heart rate \< 45 beats per minute [bpm] or > 100 bpm) at Screening or Day -1, as determined by the Investigator or designee
  11. History of, or existing severe, acute, chronic, and/or psychiatric medical condition(s), laboratory abnormality, or other medical concerns that may increase the risk associated with study participation or IMP administration which, in the judgment of the Investigator, would make the subject inappropriate for entry into the study
  12. History of cancer with the exception of adequately treated basal cell or squamous cell carcinoma of the skin
  13. \< lower limit of normal (LLN)
  14. Abnormal liver function- (ALT) or aspartate aminotransferase (AST) > 2 times the (ULN)

    • total > 1.5 times ULN
  15. Abnormal renal function: estimated (eGFR) (modification of diet and renal disease [MDRD]) \< 55 mL/min/1.73 m2
  16. Pulmonary function outside the normal range, including forced expiratory volume 1 (), forced vital capacity (FVC) each \< 80% of predicted or FEV1/FVC ratio of ≤ 0.7 at Screening
  17. Inability to use study inhaler device appropriately.
  18. Positive test results for (HIV) HIV-1/HIV-2 antibodies, surface antigen (HBsAG) or virus antibody (HCV-AB) Concurrent Intake of Other Substances
  19. History of alcohol abuse within one year prior to Screening or regular use of alcohol of ≥ 14 units of alcohol per week for females and ≥ 21 units of alcohol for males (1 unit = 150 mL wine, 360 mL beer or 45 mL of 40% alcohol) within 6 months prior to dosing or a positive urine alcohol test at Screening or Day -1
  20. History of drug abuse or misuse within 5 years prior to dosing or a positive urine drug test at Screening or Day -1
  21. Inability or unwillingness to abstain from alcohol or any drug of abuse for 48 hours prior to the first dose until completion of the Day 8 visit for the SAD and Day 21 visit for the MAD
  22. Exposure to any within 28 days prior to dosing
  23. Treatment with an product within 30 days or 5 half-lives (whichever is longer) prior to dosing
  24. Use of prescription or non-prescription medications and dietary supplements within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. Herbal supplements must be discontinued 28 days prior to dosing. Approved medications taken for are permitted.
  25. Positive serum pregnancy test in female subjects
  26. Female subjects who are lactating
  27. Female subjects of (FOCBP) and men with partners of childbearing potential who do not agree to use an acceptable form of contraception for the duration of study treatment and for at least 90 days after the last dose of study medication. Male subjects who do not agree to refrain from donating sperm during this same period.
  28. Not eligible to receive study medication within 2 weeks of receiving a COVID-19 vaccination, including an initial, second, or booster injection.

NOTE: Female who is surgically sterile or for at least 12 months with follicle stimulating hormone (FSH) > 30 mIU/ml, are not considered to be of childbearing potential.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
71 participants (actual)

Study arms

  • Sham comparator
    Placebo

    Matching placebo is a micronized lactose powder administered by inhalation through a dry powder inhaler (DPI)

    Drug: Placebo

  • Experimental
    SAD Cohort 1

    LTI-03 20 mg delivered qd x 1 day via DPI

    Drug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)

  • Experimental
    SAD Cohort 2

    LTI-03 40 mg delivered qd x 1 day via DPI

    Drug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)

  • Experimental
    SAD Cohort 3

    LTI-03 80 mg delivered qd x 1 day via DPI

    Drug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)

  • Experimental
    MAD Cohort 1

    LTI-03 dose at 20mg once daily x 14 days via DPI

    Drug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)

  • Experimental
    MAD Cohort 2

    LTI-03 dose at 40mg once daily x 14 days via DPI

    Drug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)

  • Experimental
    MAD Cohort 3

    LTI-03 dose at 2.5 mg once daily x 14 days via DPI

    Drug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)

  • Experimental
    MAD Cohort 4

    LTI-03 dose at 5 mg once daily x 14 days via DPI

    Drug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)

  • Experimental
    MAD Cohort 5

    LTI-03 dose at 5 mg twice daily x 14 days via DPI

    Drug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)

Interventions

  • LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.

  • DrugPlacebo

    Matching placebo is micronized lactose powder administered by inhalation through a dry powder inhaler.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAE)

    Incidence of TEAE by system-organ class and dose group as assessed by the Toxicity Grading Scale for Healthy Adult Volunteers

    Time frame: up to 49 days

07

Study locations

1 site
  • Celerion
    Belfast, BT9 6AD, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Dec 2021, 23 months.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 23 months is above that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2020
First posted
Jan 18, 2020
StartActual
Jan 20, 2020
Primary completionActual
Dec 23, 2021
CompletionActual
Dec 23, 2021
Last update
Mar 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04233814
Lead sponsor
Lung Therapeutics, Inc
Responsible party
Sponsor
First posted
Jan 18, 2020
Start date
Jan 20, 2020
Primary completion
Dec 23, 2021
Completion
Dec 23, 2021
Last update
Mar 7, 2022

Study contacts

Devinda Weeraratne, MD
principal investigator · Celerion

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LTI-03

Start the discussion